Literature DB >> 31999070

The Bethesda System for Reporting Thyroid Cytology (TBSRTC): From look-backs to look-ahead.

Zubair Baloch1, Virginia A LiVolsi1.   

Abstract

The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was formalized in October 2007 by experts in thyroidology at the National Institute of Health in Bethesda, Maryland. The first edition of the TBSRTC book was published in 2010 and the second edition in 2018. The TBSRTC is widely employed in cytology practices in the United States and has also served as a model for similar tiered classification schemes for reporting thyroid cytopathology specimens. The tremendous success of TBSRTC cannot be underscored, it has provided a diagnostic framework which is well aligned with the present and the future of thyroid nodule management.
© 2020 Wiley Periodicals, Inc.

Keywords:  diagnosis; reporting systems; thyroid cytology; thyroid neoplasms

Mesh:

Year:  2020        PMID: 31999070     DOI: 10.1002/dc.24385

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  4 in total

Review 1.  A Case-Based Comparison of the American Thyroid Association and Thyroid Imaging Reporting & Data System Guidelines.

Authors:  Leslie Shang; Rob Downing; Betty Drees; Lamont Weide
Journal:  Mo Med       Date:  2022 Jul-Aug

Review 2.  Contemporary Thyroid Nodule Evaluation and Management.

Authors:  Giorgio Grani; Marialuisa Sponziello; Valeria Pecce; Valeria Ramundo; Cosimo Durante
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

3.  Current classification systems and standardized terminology in cytopathology.

Authors:  Tibor Mezei
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

4.  Diagnosis of Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma by Cervical Biopsy under Colposcopy and Analysis of Factors Influencing.

Authors:  Ying Wang; Jing Wang; Hua Mei
Journal:  Emerg Med Int       Date:  2022-07-30       Impact factor: 1.621

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.